Table 2.
Heart rate in the trial group and the control group at baseline and 4 weeks.
| HR variables | Trial group | Control group | P value |
|---|---|---|---|
| AHR (bpm) | |||
| Baseline | 53.38 ± 5.16 | 53.83 ± 4.17 | 0.482 |
| 4 weeks | 60.50 ± 8.70* | 56.50 ± 5.99* | 0.000 |
| FHR (bpm) | |||
| Baseline | 95.50 ± 24.94 | 95.31 ± 20.64 | 0.952 |
| 4 weeks | 105.54 ± 24.97# | 98.93 ± 18.85 | 0.029 |
| LHR (bpm) | |||
| Baseline | 33.50 ± 3.62 | 33.98 ± 3.91 | 0.350 |
| 4 weeks | 40.74 ± 7.67# | 38.08 ± 5.85# | 0.005 |
HR: heart rate; AHR: average heart rate; FHR: fastest heart rate (bpm); LHR: lowest heart rate.
At baseline, there are 115 patients in the trial group and 104 patients in the control group. At the end of 4 weeks, 1 patient in the trial group and 4 patients in the control group refused to repeat 24-hour Holter, so their HR variables are missed.
*P < 0.05 versus pretreatment in the same group.
# P < 0.01 versus pretreatment in the same group.